FT Edit
@ftedit.ft.com
1K followers 2 following 570 posts
Eight brilliant stories from the Financial Times, updated daily. 🔎 Explore more at www.ft.com/ftedit 📧 Sign up for our newsletter: https://on.ft.com/44K0XEi
Posts Media Videos Starter Packs
Pinned
ftedit.ft.com
Welcome to FT Edit! When the news is overwhelming, we bring you eight stories a day, chosen by editors, offering clarity, fresh perspectives, insight and inspiration — plus some extra treats! Explore more at www.ft.com/ftedit or, if you're reading on iOS, find us on the FT app: on.ft.com/44SHfGA
ftedit.ft.com
The science is compelling, but the jury is out. For Novo Nordisk, it may be a risk worth taking. It's losing out in the weight loss market to US competitors and needs a share price boost. And if it means a treatment for Alzheimer’s, which affects millions of people every year, then it’s a win-win.
ftedit.ft.com
1️⃣ GLP-1s could reduce sugar in the brain that accelerates the build-up of proteins linked to the disease. This sugar could be one reason why people with obesity or diabetes are more likely to get Alzheimer’s.

2️⃣ GLP-1s can reduce inflammation in the body, one of the main causes of Alzheimer’s.
ftedit.ft.com
The magic ingredient in all this is GLP-1, a hormone that tells you when you’re full and the active ingredient in both Wegovy and Ozempic. So how could it combat Alzheimer’s? There are two theories …
ftedit.ft.com
It’s important to stress just what a moonshot this is for Novo Nordisk. Most experimental drugs for Alzheimer’s, the most common form of dementia, have failed. But with cases of the disease set to triple by 2050, the drugmaker hopes that finding an effective treatment could be its “lottery ticket”.
ftedit.ft.com
Can obesity drugs treat Alzheimer’s? Novo Nordisk, the Danish company behind Wegovy and Ozempic, is staking its future on the answer. It's been running two vast trials for more than three years and is about to publish the results.

An #FTEdit 🧵on the science behind Novo Nordisk’s big gamble 👇
ftedit.ft.com
Donald Trump’s bid to end the war in Gaza looks set to be his biggest foreign policy achievement. He missed out on a Nobel Peace Prize this year. Should he win next year? Tell us in today's #FTEdit poll: on.ft.com/4hbLykL

Read the story 👉 A rare moment of hope in the Middle East on.ft.com/4h5sGnk